Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia [Yahoo! Finance]
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target raised by analysts at HC Wainwright from $30.00 to $35.00. They now have a "buy" rating on the stock.
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at BTIG Research. They set a "buy" rating and a $35.00 price target on the stock.
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.